Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 4, July-August, p. 657–663

Publication type: review article

Language: English

Interactions Between Preparations Containing Female Sex Hormones and Dietary Supplements

Katarzyna Zabłocka-Słowińska1,A,B,C,D, Katarzyna Jawna2,A,B,C,D, Halina Grajeta1,E,F, Jadwiga Biernat3,A,E,F

1 Department of Food Science and Nutrition, Wroclaw Medical University, Poland

2 Students’ Scientific Club at the Department and Chair of Bromatology and Dietetics, Wroclaw Medical University, Poland

3 Department of Human Nutrition, Wroclaw University of Life Sciences, Poland


An increasing number of premenopausal women use contraception whereas postmenopausal women use hormone replacement therapy (HRT). This long-term hormone therapy poses a high risk of interactions with dietary supplements. Taking estrogens at the same time as selective estrogen receptor modulators (SERMs), biologically-active compounds of glycine soja, Ginkgo biloba or Pimpinella anisum, may distort the final effect of the hormone agent. On the other hand, estrogen therapy coupled with melatonin or retinol supplementation may lead to an increased level of dietary supplements in the serum as studies have proved a concomitant beneficial effect of HRT and vitamin E supplementation on lipid profiles. In turn, taking preparations containing St John’s wort during hormone therapy may lead to a reduction in hormone concentrations in serum and debilitation of the pharmacological effect. It results from the inductive effect of the biologically-active compounds of St John’s wort on the metabolism of hormones as a result of the enhanced activity of cytochrome P450 CYP3A4.

Key words

dietary supplements, interactions, hormone replacement therapy, contraception.

References (47)

  1. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hemon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw K-T, Olsen A, Tjonneland A, Rodriguez L, Sánchez MJ, Etxezarreta AP, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, Gonzáles CA, Berrino F: Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Pro
  2. Mørch LS, Løkkegaard E, Andreasen AH, Kjær SK, Lidegaard Ø: Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol 2012, 175, 1234–1242.
  3. Tsai SA, Stefanick ML, Stafford RS: Trends in menopausal hormone therapy use of US office-based physicians, 2000–2009. Menopause 2011, 18, 385–392.
  4. Rachoń D, Zdrojewski T, Suchecka-Rachoń K, Szpakowski P, Bandosz P, Manikowski A, Wyrzykowski B: Knowledge and use of hormone replacement therapy among Polish women: estimates from a nationally representative study – HORTPOL 2002. Maturitas 2004, 47, 31–37.
  5. Główny Urząd Statystyczny: Stan zdrowia ludności Polski w 2009 r., Warszawa, 2011, 78–79 (Internet: http://www.
  6. Bitzer J, Gemzell-Danielsson K, Roumen F, Marintcheva-Petrova M, van Bakel B, Oddens BJ: The CHOICE study: Effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care 2012, 17, 65–78.
  7. Birkhäuser PMH, Reinecke I: Current trends in hormone replacement therapy: perceptions and usage. Climacteric 2008, 11, 192–200.
  8. Stoia M, Oancea S: Herbal dietary supplements consumption in Romania from the perspective of public health and education. Acta Med Transilv 2013, 18, 216–219.
  9. Lentjes MA, Welch AA, Luben RN, Khaw KT: Differences in dietary supplement use and secular and seasonal trends assessed using three different instruments in the EPIC-Norfolk Population Study. J Diet Suppl 2013, 10, 142–151.
  10. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, Betz JM, Sempos CT, Picciano MF: Dietary supplement use in the United States, 2003–2006. J Nutr 2011, 141, 261–266.
  11. Rovira MA, Grau M, Castañer O, Covas MI, Schröder H: Dietary supplement use and health-related behaviors in a Mediterranean population. J Nutr Educ Behav 2012, 45, 386–391.
  12. Timbo BB, Ross MP, McCarthy PV, Lin CTJ: Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc 2006, 106, 1966–1974.
  13. Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB: Tissue distribution of estrogen receptors alpha (ER-α) and beta (ER-β) mRNA in the midgestational human fetus. J Clin Endocrinol Metabol 1997, 82, 3509–3512.
  14. Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, Thomas GD, Mineo C, Yuhanna IS, Kim SH, Madak-Erdogan Z, Maggi A, Dineen SP, Roland CL, Hui DY, Brekken RA, Katzenellenbogen JA, Katzenellenbogen BS, Shaul PW: Non-nuclear estrogen receptor α signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 2010, 120, 2319–2330.
  15. Hogan AM, Collins D, Sheehan K, Zierau O, Baird AW, Winter DC: Rapid effects of phytoestrogens on human colonic smooth muscle are mediated by oestrogen receptor β. Mol Cell Endocrinol 2010, 320, 106–110.
  16. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V,Montanaro D, Musti AM, Picard D, Andò S: The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004, 279, 27008–27016.
  17. Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young R, Barnes S, Konzelmann KL, Fisher JG, Ellis KJ, Shypailo RJ, Fraley JK, Smith EO, Wong WW: Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr 2011, 93, 356–367.
  18. Saggar JK, Chen J, Corey P, Thompson LU: Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptorand growth factor-signaling pathways. Mol Nutr Food Res 2010, 54, 415–425.
  19. Hong YH, Wang SC, Hsu C, Lin BF, Kuo YH, Huang C. Phytoestrogenic compounds in alfalfa sprout (Medicago sativa) beyond coumestrol. J Agric Food Chem 2010, 59, 131–137.
  20. Jiang Y, Gong P, Madak-Erdogan Z, Martin T, Jeyakumar M, Carlson K, Khan I, Smillie TJ, Chittiboyina AG, Rotte SCK, Helferich WG, Katzenellenbogen JA, Katzenellenbogen BS: Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens. The FASEB Journal 2013, 27, 4406–4418.
  21. Sotoca AM, Gelpke MDS, Boeren S, Ström A, Gustafsson JÅ, Murk AJ, Rietjens IMCM, Vervoort J: Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteom 2011, 10, M110.002170. DOI: 10.1074/mcp. M110.002170.
  22. Losa SM, Todd KL, Sullivan AW, Cao J, Mickens JA, Patisaul HB: Neonatal exposure to genistein adversely impacts the ontogeny of hypothalamic kisspeptin signaling pathways and ovarian development in the peripubertal female rat. Reprod Toxicol 2011, 31, 280–289.
  23. Gaete L, Tchernitchin AN, Bustamante R, Villena J, Lemus I, Gidekel M, Cabrera G, Astorga P: Daidzein–estrogen interaction in the rat uterus and its effect on human breast cancer cell growth. J Med Food 2012, 15, 1081–1090.
  24. Kang HB, Zhang YF, Yang JD, Lu KL: Study on soy isoflavone consumption and risk of breast cancer and survival. Asian Pac J Cancer Prev 2012, 13, 995–998.
  25. Xu X, Duncan AM, Merz BE, Kurzer MS: Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev 1998, 7, 1101–1108.
  26. Suparto IH, Williams JK, Fox JL, Yusuf JTL, Sajuthi D: Effects of hormone therapy and dietary soy on myocardial ischemia/reperfusion injury in ovariectomized atherosclerotic monkeys. Menopause 2008, 15, 256–263.
  27. Sueng-Min O, Kyu-Hyuck C: Estrogenic activities of Ginkgo biloba extracts. Life Sci 2004, 74, 1325–1335.
  28. Hassan WN, Saed AM: Protective effect of Anise Fruit (Pimpinella anisum) against osteoporosis in rat model. Am J Biomed Sci 2011, 3, 49–56.
  29. Tabanca N, Khan SI, Bedir E, Annavarapu S, Willett K, Khan IA, Kirimer N, Baser KH: Estrogenic activity of isolated compounds and essential oils of Pimpinella species from Turkey, evaluated using a recombinant yeast screen. Planta Med 2004, 70, 728–735.
  30. Kassi E, Papoutsi Z, Fokialakis N, Messari I, Mitakou S, Moutsatsou P: Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties. J Agric Food Chem 2004, 52, 6956–6961.
  31. Ochoa-Sanchez R, Rainer Q, Comai S, Spadoni G, Bedini A, Rivara S, Fraschini F, Mor M, Tarzia G, Gobbi G: Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. Prog Neuro-Psychopharmacol Biol Psych 2012, 39, 318–325.
  32. Hilli J, Korhonen T, Turpeinen M, Hokkanen J, Mattila S, Laine K: The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 polymorphism. J Clin Pharmacol 2008, 48, 986–994.
  33. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J: Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003, 56, 683–690.
  34. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC: The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 2003, 74, 525–535.
  35. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL: Interaction of St John’s wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005, 71, 402–408.
  36. Sigłowa A, Bertrandt B, Conder M, Bertrandt K, Lisiecka A, Kubiak P, Urbańska A: Suplementacja diety wśród studentów. Żywność Nauka Technologia Jakość 2009, 65, 236–249.
  37. Myung SK, Kim Y, Ju W, Choi HJ, Bae WK: Effects of antioxidant supplements on cancer prevention: metaanalysis of randomized controlled trials. Ann. Oncol 2010, 21, 166–179.
  38. Vihtamaki T, Parantainen J, Koivisto AM, Metsa-Ketela T, Tuimala R: Oral ascorbic acid increases plasma oestradiol during postmenopausal hormone replacement therapy. Maturitas 2002, 42, 129–135.
  39. Yeung DL: Effect of oral contraceptives on vitamin A metabolism in the human and the rat. Am J Clin Nutr 1974, 27, 125–129.
  40. Thane CW, Bates CJ, Prentice A: Oral contraceptives and nutritional status in adolescent British girls. Nutr Res 2002, 22, 449–462.
  41. Wander RC, Du S-H, Ketchum S, Rowe KE: Effects of interaction of RRR-a-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy. Am J Clin Nutr 1996, 63, 184–193.
  42. Edlefsen KL, Jackson RD, Prentice RL, Janssen I, Rajkovic A, O’Sullivan MJ, Anderson G: The effects of postmenopausal hormone therapy on serum estrogen, progesterone and sex hormone binding globulin levels in healthy post-menopausal women. Menopause 2010, 17, 622.
  43. Stegeman BH, Raps M, Helmerhorst FM, Vos HL, van Vliet HAAM, Rosendaal FR, van Hylckama Vlieg A: Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone‐binding globulin levels in premenopausal women. J Thromb Haemost 2013, 11, 203–205.
  44. Nayeem F, Nagamani M, Anderson KE, Huang Y, Grady JJ, Lu LJW: Dietary beta-tocopherol and linoleic acid, serum insulin, and waist circumference predict circulating sex hormone-binding globulin in premenopausal women, J Nutr 2009, 139, 1135–1142.
  45. Akinloye O, Adebayo TO, Oguntibeju OO, Oparinde DP, Ogunyemi EO: Effects of contraceptives on serum trace elements, calcium and phosphorus levels. West Indian Med J 2011, 60, 308–315.
  46. Beneš B, Spěváčková V, Šmid J, Batáriová A, Čejchanová M, Zitková L: Effect of age, BMI, smoking and contraception on levels of Cu, Se an Zn in the blood of the population in the Czech Republic. Cent Eur J Publ Health 2005, 13, 202–207.
  47. Bureau I, Anderson RA, Arnaud J, Raysiguier Y, Favier AE, Roussel AM: Trace mineral status in postmenopausal women: impact of hormonal replacement therapy. J Trace Elem Med Biol 2002, 16, 9–13.